1

2
James Doherty
Clifton John Blankley, Diane Harris Boschelli, Annette Marian Doherty, James Marino Hamby, Sylvester Klutchko, Robert Lee Panek: Pyrido�2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Warner Lambert Company, Charles W Ashbrook, March 31, 1998: US05733914 (48 worldwide citation)

6-Aryl pyrido�2,3-d!pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.


3
James Doherty
Clifton J Blankley, Diane H Boschelli, Annette M Doherty, James M Hamby, Sylvester Klutchko, Robert L Panek: Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Warner Lambert Company, Charles W Ashbrook, April 15, 1997: US05620981 (42 worldwide citation)

6-Aryl pyrido[2,3-d]pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.


4
Bruce D Roth: [R-(R*R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-( 1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof. Warner Lambert Company, Ronald A Daignault, December 28, 1993: US05273995 (307 worldwide citation)

[R-(R*,R*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-((1-methylethyl)- 3-phenyl-4-[(phenylamino)-carbonyl]-1H-pyrrole-1-heptanoic acid or (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl-N,4-diphenyl-1-[2-(tetrahyd ro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide; and pharmaceutic ...


5
Bruce D Roth: Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. Warner Lambert Company, Jerry F Janssen, July 21, 1987: US04681893 (251 worldwide citation)

Certain trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase and are thus useful hypolipidemic or hyp ...


6

7
Colin D Granger, Thomas H Simon: Misuse-resistive transdermal opioid dosage form. Warner Lambert Company, Richard S Bullitt, September 22, 1992: US05149538 (234 worldwide citation)

A misuse-resistive dosage form for the transdermal delivery of opioid comprises, in combination, 1) one or more opioid permeable to the skin, 2) delivery means permeable to said opioid, 3) one or more antagonist for said opioid releasable upon ingestion or solvent immersion, and 4) impermeable barri ...


8

9
Donna R Cody, Sheila H H DeWitt, John C Hodges, John S Kiely, Walter H Moos, Michael R Pavia, Bruce D Roth, Mel C Schroeder, Charles J Stankovic: Apparatus for multiple simultaneous synthesis. Warner Lambert Company, Charles W Almer III, Francis J Tinney, June 28, 1994: US05324483 (194 worldwide citation)

An apparatus and method which provides a suitable location for multiple, simultaneous synthesis of compounds. The apparatus consists of: a reservoir block having a plurality of wells; a plurality of reaction tubes, usually gas dispersion tubes, having filters on their lower ends; a holder block, hav ...


10
Fritz Wittwer, Ivan Tomka: Polymer composition for injection molding. Warner Lambert Company, Howard Olevsky, Stephen Raines, June 16, 1987: US04673438 (181 worldwide citation)

Capsules and other shaped products formed from a moldable starch composition in an injection molding device is disclosed in the present invention. The composition comprising starch having a molecular mass range of 10,000 to 20,000,000 Dalton, and a water content range from 5 to 30% by weight. The st ...